Do not do in COPD: consensus statement on overuse
- PMID: 29440883
- PMCID: PMC5799849
- DOI: 10.2147/COPD.S151939
Do not do in COPD: consensus statement on overuse
Abstract
Background: To identify practices that do not add value, cause harm, or subject patients with chronic obstructive pulmonary disease (COPD) to a level of risk that outweighs possible benefits (overuse).
Methods: A qualitative approach was applied. First, a multidisciplinary group of healthcare professionals used the Metaplan technique to draft and rank a list of overused procedures as well as self-care practices in patients with stable and exacerbated COPD. Second, in successive consensus-building rounds, description files were created for each "do not do" (DND) recommendation, consisting of a definition, description, quality of supporting evidence for the recommendation, and the indicator used to measure the degree of overuse. The consensus group comprised 6 pulmonologists, 2 general practitioners, 1 nurse, and 1 physiotherapist.
Results: In total, 16 DND recommendations were made for patients with COPD: 6 for stable COPD, 6 for exacerbated COPD, and 4 concerning self-care.
Conclusion: Overuse poses a risk for patients and jeopardizes care quality. These 16 DND recommendations for COPD will lower care risks and improve disease management, facilitate communication between physicians and patients, and bolster patient ability to provide self-care.
Keywords: COPD; consensus; patient safety; quality assurance.
Conflict of interest statement
Disclosures F Villar-Álvarez, R Moreno-Zabaleta, JJ Mira-Solves, E Calvo-Corbella, S Díaz-Lobato, F González-Torralba, A Hernando-Sanz, S Salgado-Aranda, B Simón-Rodríguez, and IM Navarro-Soler report no conflicts of interest in this work. S Núñez-Palomo declares that she has written monographs or participated in courses and conferences sponsored by Boehringher, Pfizer, Astra Zéneca, GSK, and Rovi, and has no other conflicts of interest in this work. P Vaquero-Lozano declares that in the last 5 years he has received payments for participating in meetings or congresses organized by the following pharmaceutical companies: Chiesi, AstraZeneca, Boehringer-Ingelheim, Almirall, Novartis, Sandoz, Pfizer, and Linde (Carburos Médica), and has no other conflicts of interest in this work.
Figures
References
-
- University of Colorado School of Medicine Do No Harm Project. [Accessed September 13, 2017]. Available from: http://www.ucdenver.edu/academics/colleges/medi-calschool/departments/me....
-
- Bishop TF, Cea M, Miranda Y, et al. Academic physicians’ views on low-value services and the choosing wisely campaign: a qualitative study. Healthc (Amst) 2017;5(1–2):17–22. - PubMed
-
- Wise J. Choosing Wisely: how the UK intends to reduce harmful medical overuse. BMJ. 2017;356:j370. - PubMed
-
- Less is More Medicine. [Accessed September 13, 2017]. Available from: http://www.lessismoremedi-cine.com/
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
